<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C0085278" disease_type="Disease or Syndrome" abbrv="">Antiphospholipid syndrome</z:e> is characterized by <z:mp ids='MP_0005048'>thrombosis</z:mp>, recurrent fetal loss, and the presence of the <z:e sem="disease" ids="C0024138,C0024141,C0024131,C0409974" disease_type="Disease or Syndrome" abbrv="">lupus</z:e> <z:chebi fb="3" ids="50249">anticoagulant</z:chebi>, anticardiolipin antibodies, or anti-β(2)-<z:chebi fb="2" ids="17089">glycoprotein</z:chebi>-1 (anti-β(2)-GP1) antibodies </plain></SENT>
<SENT sid="1" pm="."><plain>Although anti-β(2)-GP1 antibodies have been documented as a biomarker for diagnosis of <z:e sem="disease" ids="C0085278" disease_type="Disease or Syndrome" abbrv="">antiphospholipid syndrome</z:e>, their direct role in the pathogenesis of <z:mp ids='MP_0005048'>thrombosis</z:mp> is unknown </plain></SENT>
<SENT sid="2" pm="."><plain>We have demonstrated using intravital microscopy that anti-β(2)-GP1 autoantibodies purified from the sera of patients with <z:e sem="disease" ids="C0085278" disease_type="Disease or Syndrome" abbrv="">antiphospholipid syndrome</z:e> complicated by <z:mp ids='MP_0005048'>thrombosis</z:mp> greatly amplify <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> size after laser-induced vessel wall injury in live mice </plain></SENT>
<SENT sid="3" pm="."><plain>Anti-β(2)-GP1 autoantibodies from 3 patients with <z:e sem="disease" ids="C0085278" disease_type="Disease or Syndrome" abbrv="">antiphospholipid syndrome</z:e> were affinity-purified using human β(2)-GP1 bound to <z:chebi fb="2" ids="2511">agarose</z:chebi> </plain></SENT>
<SENT sid="4" pm="."><plain>The effects of purified anti-β(2)-GP1 IgG autoantibodies, of anti-β(2)-GP1-depleted IgG, and of IgG from <z:mpath ids='MPATH_458'>normal</z:mpath> human sera on <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> formation were measured in mice after arterial injury in the cremaster muscle </plain></SENT>
<SENT sid="5" pm="."><plain>Before injury, purified anti-β(2)-GP1 IgG autoantibodies, anti-β(2)-GP1 antibody-depleted IgG, or IgG from <z:mpath ids='MPATH_458'>normal</z:mpath> human sera were infused </plain></SENT>
<SENT sid="6" pm="."><plain>Increasing amounts of purified anti-β(2)-GP1 autoantibodies increased <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> size in a dose-dependent manner, whereas neither anti-β(2)-GP1 antibody-depleted IgG nor IgG from <z:mpath ids='MPATH_458'>normal</z:mpath> serum affected <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> size </plain></SENT>
<SENT sid="7" pm="."><plain>These results indicate that anti-β(2)-GP1 IgG autoantibodies in <z:e sem="disease" ids="C0085278" disease_type="Disease or Syndrome" abbrv="">antiphospholipid syndrome</z:e> patient sera are not only a marker of <z:e sem="disease" ids="C0085278" disease_type="Disease or Syndrome" abbrv="">antiphospholipid syndrome</z:e> but are directly involved in the pathogenesis of <z:mp ids='MP_0005048'>thrombosis</z:mp> </plain></SENT>
</text></document>